Heidi Grabenstatter

Heidi Grabenstatter has extensive experience in scientific research and academia. Heidi is currently working as the Scientific Director for RDCA-DAP at Critical Path Institute (C-Path) since 2023. Prior to this, they held various roles at the University of Colorado Boulder, including Affiliate Faculty and Senior Research Scientist from 2015 to 2021. Their research focused on molecular mechanisms and methods to inhibit pharmacoresistant epilepsy. Heidi also conducted in vivo EEG/EKG monitoring of rodent epilepsy models to better understand abnormal physiology in the epileptic heart. In 2018, Heidi served as the Science Director at the International Foundation for CDKL5 Research (IFCR). Before that, they worked as a Postdoctoral Research Fellow at the University of Colorado Anschutz Medical Campus from 2009 to 2015, where they studied the reactivation of signal pathways and changes in GABA(A) receptor subunits expression in pilocarpine-treated rats with epilepsy. Heidi also evaluated the role of STAT3 phosphorylation in the progression of epileptogenesis. Heidi's research career began as a Postdoctoral Research Fellow at the University of Wisconsin-Madison from 2007 to 2009.

Heidi Grabenstatter holds a Ph.D. in Molecular, Cellular, and Integrative Neuroscience, which they obtained from Colorado State University from 2001 to 2007. Prior to their Ph.D., they earned a Master of Science degree in Biomedical Sciences with a specialization in Anatomy/Neurobiology from Colorado State University between 2001 and 2003. Heidi's education journey began at Colorado State University in 1996, where they completed their Bachelor of Science degree in Microbiology.